Biotech News

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

Erasca (ERAS)ErascaEarnings

ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect

Related news

Erasca

RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....

Recent company news

Stock data

Close
14.22 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States